Dr. Carl H. June, MD, of the University of Pennsylvania, who is one of the pioneers of CAR-T cell therapy, will share all about his CAR T-Cell Journey and the Cancer Treatment Revolution with CureTalks on November 15, 2017, 1 PM EST.
Juno Therapeutics may have lost the initial race for FDA approval of CAR-T (to Novartis and Gilead [Kite]), but they are preparing to demonstrate at December’s ASH 17 conference (American Society of Hematology), that theirs is the superior CAR-T therapy:
The analogy I’ll give you,” says R&D chief Sunil Agarwal: “Small changes in the antibody world can make big differences; all CARs are not the same… I think these data continue to support a best-in-class profile.”
(FYI, The CAR-T therapy I underwent at MSK in 2015 was in partnership with Juno, although the protocol was not JCAR017)
October 31, 2017 Newswise — ROCHESTER, Minn. – Mayo Clinic announced today that its Rochester campus is one of 16 cancer centers nationally selected to provide chimeric antigen receptor T-cell therapy (CAR T-cell therapy) for adults with B-cell non-Hodgkin lymphoma who have not responded to, or have relapsed, after two or more lines of treatment. The therapy, called axicabtagene ciloleucel (Yescarta), is approved to treat subtypes of lymphoma, including diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, diffuse large B-cell lymphoma arising from follicular lymphoma, and high-grade B-cell lymphoma.
The logical next step in the evolution of CAR-T has occurred. Novartis’ Kymriah has already been approved for leukemia, while Gilead’s (originally Kite’s) Yescarta has been approved for diffuse large B-cell lymphoma (DLBCL). Now Novartis has filed for approval of Kymriah for DLBCL as well:
“The fantastic voyage of a bag of cells hot-wired to kill cancer”
Thanks to references from Lympho Bob and the Facebook group CAR T-CELL Patients And Carers, this blog has recently received upwards of 20 visits per day. However, we’ve noticed that most visitors are finding little content to actually “click through”. Perhaps the coverage here is not relevant to the typical reader?
So we ask you to please do us a small favor… Just take a moment to leave a comment here detailing what brought you here, what you were hoping to find, and what you think should be here on this blog. We certainly don’t want to waste anyone’s time with information they deem irrelevant or uninteresting, and we want this blog to be a useful resource for readers. Your feedback would be most appreciated!
— Ben & Bill